Ignite Creation Date:
2024-05-05 @ 11:02 PM
Last Modification Date:
2024-10-26 @ 10:28 AM
Study NCT ID:
NCT01248429
Status:
COMPLETED
Last Update Posted:
2012-06-07
First Post:
2010-11-24
Brief Title:
Prevalence of Creatinine Phosphokinase Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases
Sponsor:
Centre Oscar Lambret
Organization:
Centre Oscar Lambret
Study Overview
Official Title:
National Study of Prevalence of Creatinine Phosphokinase CPK Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases TKI
Status:
COMPLETED
Status Verified Date:
2012-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TKI-CPK-1003
Brief Summary:
This study describes the elevation of CPK in patient treated for solid tumors by TKI
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None